Phase II study of weekly 4′-epidoxorubicin in patients with metastatic squamous cell cancer of the cervix: An EORTC Gynaecological Cancer Cooperative Group Study

M. E L van der Burg, S. Monfardini, J. P. Guastalla, C. de Oliveira, J. Renard, J. B. Vermorken

Research output: Contribution to journalArticlepeer-review

Abstract

In this study 24 patients with metastatic cervical cancer were treated with a weekly bolus injection of 4′-epidoxorubicin at a dose of 12.5 mg/m2. All patients were followed until disease progression. Toxicity was generally absent or very mild. Only 1 patient (4%) had a partial remission lasting 23 weeks and 9 patients (38%) had stable disease with a median duration of 13 weeks (range 7-36). 4′-Epidoxorubicin at this dose and schedule is not active in metastatic squamous cell carcinoma of the cervix.

Original languageEnglish
Pages (from-to)147-148
Number of pages2
JournalEuropean Journal of Cancer
Volume29
Issue number1
DOIs
Publication statusPublished - 1993

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Phase II study of weekly 4′-epidoxorubicin in patients with metastatic squamous cell cancer of the cervix: An EORTC Gynaecological Cancer Cooperative Group Study'. Together they form a unique fingerprint.

Cite this